Recent Updates
Recently added Catalysts
FATE Neutral Sentiment Score: 50/100

Development of Next Generation Multi-Antigen Targeting Off-the Shelf CAR T-Cells for Conditioning-Free Treatment of B-Cell Lymphoma

Monday, December 8, 2025 1 min read
Key Takeaway: The article discusses the development of next-generation CAR T-cells aimed at treating B-cell lymphoma without the need for conditioning. It highlights the innovative approach of multi-antigen targeting to enhance treatment efficacy. However, specific details regarding the research progress or results are not provided.
Price reaction · baseline $1.08 (2025-12-05 close) · hit pre-market · clean, no other FATE news in the window
day 0 close · peak
-0.9%

Market Sentiment Analysis

Full Press Release Details

• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Tags: FATE Viatris Investor Conferences Healthcare CAR T-cells B-cell lymphoma multi-antigen targeting
Last updated: Dec 8, 2025

Biotech snapshot

Cash runway
$175M liquidity · $10M/mo burn
~15 mo
Low dilution risk
Lead asset
FT825Phase 1
Advanced Solid Tumor →

Catalyst track record

+215%
best trade around FATE's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for FATE.

See every catalyst's timing & PoA →